Veracyte (VCYT) Reiterated at Buy by UBS: 2026 Revenue Guidance Above Street

UBS analyst Lu Li reiterated a Buy rating and $48.00 price target on Veracyte, Inc (NASDAQ: VCYT).

The analyst commented, "The company's Q4 testing revenue beat was likely due to higher ASP/ prior period collection with in-line Decipher volume growth (rather than a beat). However, the company guides 2026 testing revenue above Street and maintains 25% adj. EBITDA margin, which we consider positive and new product contribution represents potential upside."

For an analyst ratings summary and ratings history on Veracyte, Inc click here. For more ratings news on Veracyte, Inc click here.

Shares of Veracyte, Inc closed at $42.04 yesterday.

You May Also Be Interested In

• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• DA Davidson Reiterates Neutral Rating on Timken (TKR)
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results